Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition(s):Autosomal Dominant Polycystic Kidney DiseaseLast Updated:March 5, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Autosomal Dominant Polycystic Kidney DiseaseLast Updated:March 5, 2019Completed
Condition(s):Nephrolithiasis, Calcium Oxalate; Nephrolithiasis, Calcium PhosphateLast Updated:March 30, 2016Completed
Condition(s):Decompensated Heart Failure; HyponatremiaLast Updated:August 10, 2018Unknown status
Condition(s):Healthy VolunteersLast Updated:September 10, 2019Unknown status
Condition(s):Autosomal Recessive Polycystic Kidney Disease (ARPKD)Last Updated:September 15, 2023Recruiting
Condition(s):Advanced CancersLast Updated:September 23, 2020Completed
Condition(s):SIADH; Non-SIADH Hyponatremia; Non-HyponatremiaLast Updated:May 1, 2013Unknown status
Condition(s):Ascites; Hepatic CirrhosisLast Updated:October 12, 2012Completed
Condition(s):HyponatremiaLast Updated:January 21, 2016Completed
Condition(s):Heart Failure; DyspneaLast Updated:April 27, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.